Focal Epilepsy

Neurology
12
Pipeline Programs
5
Companies
9
Clinical Trials
2 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
2
1
5
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

UP
KEPPRAApproved
levetiracetam
UCB Pharma
oral2003
UP
KEPPRA XRApproved
levetiracetam
UCB Pharma
oral2008
U
LEVETIRACETAMApproved
levetiracetam
Unknown Company
oral2012
U
SPRITAMApproved
levetiracetam
Unknown Company
oral2015

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
2 programs
1
1
LevetiracetamPhase 41 trial
LacosamidePhase 21 trial
Active Trials
NCT01724918Terminated72Est. Aug 2016
NCT00438451Completed361Est. Aug 2011
Xenon Pharmaceuticals
2 programs
1
1
XEN1101Phase 31 trial
XEN1101Phase 21 trial
Active Trials
NCT03796962Active Not Recruiting325Est. Oct 2028
NCT05718817Enrolling By Invitation880Est. Sep 2028
Biohaven
BiohavenNEW HAVEN, CT
3 programs
1
2
BHV-7000Phase 2/31 trial
BHV-7000Phase 2/31 trial
BHV-7000Phase 21 trial
Active Trials
NCT06443463Enrolling By InvitationEst. Jan 2027
NCT06132893RecruitingEst. Dec 2026
NCT06309966RecruitingEst. May 2026
Engrail Therapeutics
Engrail TherapeuticsCA - San Diego
1 program
1
ENX-101Phase 21 trial
Active Trials
NCT05481905Withdrawn0Est. Dec 2024
E
EisaiChina - Liaoning
1 program
ZEDEBAC: Zebinix Effects in Dependency of Baseline ConditionsN/A1 trial
Active Trials
NCT03082222Completed246Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
UCB PharmaLevetiracetam
Xenon PharmaceuticalsXEN1101
BiohavenBHV-7000
BiohavenBHV-7000
BiohavenBHV-7000
Engrail TherapeuticsENX-101
Xenon PharmaceuticalsXEN1101
UCB PharmaLacosamide
EisaiZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Clinical Trials (9)

Total enrollment: 1,884 patients across 9 trials

NCT00438451UCB PharmaLevetiracetam

Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs

Start: Jan 2007Est. completion: Aug 2011361 patients
Phase 4Completed
NCT05718817Xenon PharmaceuticalsXEN1101

An Open-label Study of XEN1101 in Epilepsy

Start: Apr 2023Est. completion: Sep 2028880 patients
Phase 3Enrolling By Invitation
NCT06309966BiohavenBHV-7000

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Start: May 2024Est. completion: May 2026
Phase 2/3Recruiting
NCT06132893BiohavenBHV-7000

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Start: Mar 2024Est. completion: Dec 2026
Phase 2/3Recruiting
NCT06443463BiohavenBHV-7000

Long-term Safety and Tolerability of BHV-7000

Start: Jul 2024Est. completion: Jan 2027
Phase 2Enrolling By Invitation
NCT05481905Engrail TherapeuticsENX-101

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

Start: Sep 2022Est. completion: Dec 20240
Phase 2Withdrawn
NCT03796962Xenon PharmaceuticalsXEN1101

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Start: Jan 2019Est. completion: Oct 2028325 patients
Phase 2Active Not Recruiting
NCT01724918UCB PharmaLacosamide

Lacosamide IV and EEG/EKG (LIVE) Study

Start: May 2013Est. completion: Aug 201672 patients
Phase 2Terminated
NCT03082222EisaiZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Start: Jul 2015Est. completion: Oct 2018246 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
6h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
6h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
6h ago

Director of Finance

CoMind
London, UK
6h ago

Electronics Engineering Manager

CoMind
London, UK
6h ago

Director of Information Technology

Zavation Medical Products
6h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,884 patients
5 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)